Cencora Reports 3.8% Revenue Growth to $78.4 Billion in Q2 Fiscal 2026

Cencora, Inc. reported its financial results for the second quarter of fiscal 2026, revealing a revenue increase of 3.8% to $78.4 billion compared to $75.5 billion in the same period last year. For the six months ending March 31, 2026, revenue rose by 4.7% to $164.3 billion, up from $156.9 billion. The company's net income for the quarter was $1.6 billion, or $8.44 per share, significantly higher than the $717.4 million, or $3.70 per share, reported in the prior year. For the six-month period, net income reached $2.2 billion, compared to $1.2 billion in the previous year.

The company experienced notable growth in its U.S. Healthcare Solutions segment, which saw revenue increase by 2.9% to $68.8 billion for the quarter and 4.0% to $145.0 billion for the six months. This growth was primarily driven by increased sales of specialty products and products labeled for diabetes and weight loss. The International Healthcare Solutions segment also contributed to the overall revenue growth, with a 13.0% increase in quarterly revenue to $7.6 billion and an 11.2% increase for the six-month period to $15.2 billion, largely due to sales growth in its European distribution business.

Cencora's operational metrics reflected a strategic focus on acquisitions, including the recent purchase of OneOncology for $7.4 billion, which was finalized in February 2026. This acquisition is expected to enhance the company's relationships with community oncology providers and strengthen its position in specialty pharmaceuticals. The company also reported a significant increase in operating expenses, which rose by 20.9% to $2.4 billion for the quarter, driven by the OneOncology acquisition and other strategic initiatives. Total operating income increased by 6.0% to $1.3 billion for the quarter.

The company’s balance sheet showed total assets of $81.7 billion as of March 31, 2026, up from $76.6 billion at the end of the previous fiscal year. Total liabilities increased to $78.1 billion, with long-term debt rising to $12.2 billion from $7.5 billion. Cencora's cash and cash equivalents decreased to $2.2 billion from $4.4 billion, reflecting significant cash outflows related to acquisitions and operational activities. The company also reported an accrued litigation liability of $4.3 billion related to opioid litigation, which is expected to be paid over the next 13 years.

Looking ahead, Cencora anticipates continued revenue growth driven by market trends, including the introduction of new therapies and the expansion of its product offerings. The company remains focused on managing its operational efficiency and leveraging its recent acquisitions to enhance its market position. However, it acknowledges potential risks from economic conditions, regulatory changes, and competitive pressures that could impact its future performance.